Self-Amplifying RNA Vaccines: Can Lower Doses Work?

How do self-amplifying RNA vaccines work?

The IndexBox outlook links rising demand for nucleic acid ingredients to vaccine and gene therapy development. That commercial forecast provides context for an important pharmaceutical advance: obtaining a useful immune response from a smaller quantity of injected RNA. The forecast itself does not demonstrate clinical benefit or establish how much any vaccine will cost. [IndexBox market outlook](https://www.indexbox.io/blog/nucleic-acid-raw-materials-market-forecast-to-2035-growth-accelerates-on-mrna-vaccine-and-gene-therapy-demand/).

Kostaive, also called zapomeran and studied as ARCT-154, delivers RNA inside small fat particles. Its instructions produce both the coronavirus spike protein and an enzyme called replicase, which generates additional RNA copies carrying the spike instructions. The immune system responds to the resulting protein. These components are subsequently broken down and removed; amplification does not continue indefinitely. Kostaive received European Union authorization on February 12, 2025, for adults aged 18 and older. This established approval illustrates that the approach has progressed beyond laboratory research. [European Medicines Agency overview](https://www.ema.europa.eu/en/medicines/human/EPAR/kostaive).

What did the lower-dose COVID-19 booster trial show?

A double-blind, randomized phase 3 trial published in The Lancet Infectious Diseases enrolled 828 adults who had already received three mRNA vaccine doses. Participants received ARCT-154 or BNT162b2 as their fourth dose. About one month later, ARCT-154 met the prespecified noninferiority criteria against the ancestral coronavirus strain, meaning its immune response was not worse beyond the trial's permitted margin. Responses against the Omicron BA.4/5 variant also met the study's superiority criteria. [Published booster trial](https://pubmed.ncbi.nlm.nih.gov/38141632/).

The distinction between immune response and clinical protection matters. This comparison assessed neutralizing antibodies; it did not establish that ARCT-154 prevented more hospitalizations or deaths than BNT162b2. The participants were previously vaccinated adults, so the findings cannot automatically be extended to children or people receiving their first vaccine. The tested formulations and variants also belong to that study period. Interpreting the results as proof of superiority against every subsequently circulating variant would go beyond the evidence. [Trial findings and interpretation](https://pubmed.ncbi.nlm.nih.gov/38141632/).

Could smaller RNA doses make vaccination more accessible?

The potential manufacturing advantage is straightforward: if other conditions were equivalent, a smaller RNA dose could allow a given quantity of finished RNA to supply more vaccinations. That is an inference from dose size, not a demonstrated reduction in total manufacturing costs. Different vaccine platforms have different production requirements. WHO guidance emphasizes that RNA vaccine manufacture also requires control of unwanted RNA species, residual production materials and other impurities. Those requirements remain relevant when the amount injected is small. [WHO regulatory considerations for mRNA vaccines](https://www.who.int/publications/m/item/annex-3-mRNA-vaccines-trs-no-1039).

A lower RNA mass also does not automatically mean fewer side effects. EMA lists injection-site discomfort, tiredness, headache and other usually short-lived reactions among Kostaive's common adverse effects. Its product information specifies a 5-microgram dose, but that amount should not be interpreted as a general instruction to reduce doses of other vaccines. Each product requires its own evidence and approved schedule. For patients, the practical issue is which authorized formulation is recommended locally for their circumstances. [Kostaive product information](https://www.ema.europa.eu/en/documents/product-information/kostaive-epar-product-information_en.pdf).